Comparative Efficacy of Interventions for Aggressive and Agitated Behaviors in Dementia

@article{Watt2019ComparativeEO,
  title={Comparative Efficacy of Interventions for Aggressive and Agitated Behaviors in Dementia},
  author={Jennifer A Watt and Zahra Goodarzi and Areti Angeliki Veroniki and Vera Nincic and Paul A. Khan and Marco Ghassemi and Yuan Thompson and Andrea C. Tricco and Sharon E. Straus},
  journal={Annals of Internal Medicine},
  year={2019},
  volume={171},
  pages={633-642}
}
Dementia, which affects 50 million people worldwide, is characterized by progressive and deleterious effects on cognition and function (1, 2). As many as 75% of persons with dementia experience neuropsychiatric (behavioral and psychological) symptoms, including aggression, agitation, and anxiety (3, 4). Compared with those who do not have neuropsychiatric symptoms, these persons are institutionalized earlier and have poorer ability to complete activities of daily living (ADLs), greater… 

Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress

TLDR
Current knowledge of the management of BPSD and its limitations is reviewed and on-going clinical trials and future therapeutic options are discussed.

Managing neuropsychiatric symptoms in patients with dementia

TLDR
Evidence of low to moderate quality shows that multidisciplinary care and non-medication interventions are as effective, or more so, than medications for reducing neuropsychiatric symptoms.

Psychosis in Alzheimer disease — mechanisms, genetics and therapeutic opportunities

TLDR
Of the currently available antipsychotic drugs, aripiprazole seems to provide the best balance between efficacy and safety in people with AD psychosis; pimavanserin has shown promise in Parkinson disease-related psychosis and data from AD trials are compelling.

Over the top: psychotropic polypharmacy in long-term care

TLDR
A meta-analysis of 25 unique studies found that one-third of long-term care residents with dementia received two-or-more psychotropic medications, and no evidence supports combining multiple psychotropics in people with dementia, outside of the treatment of mental health disorders such as psychotic depression or bipolar disorder.

Effects of Sport Stacking on Neuropsychological, Neurobiological, and Brain Function Performances in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment: A Randomized Controlled Trial

TLDR
It is suggested that sport stacking is effective for patients with MCI and mild AD, possibly through increasing the expression of neuroprotective growth factors and enhancing neural plasticity to improve neurocognitive performance.

Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis

TLDR
Although antipsychotics were associated with greater harm than antidepressants and anticonvulsants in subgroups of persons with dementia, medications used in lieu of antipsychotic for treating neuropsychiatric symptoms in dementia, such as anticonVulsants and dextromethorphan-quinidine, were also associated with harm.

References

SHOWING 1-10 OF 45 REFERENCES

Efficacy and Tolerability of Risperidone, Yokukansan, and Fluvoxamine for the Treatment of Behavioral and Psychological Symptoms of Dementia: A Blinded, Randomized Trial

TLDR
Risperidone, yokukansan or fluvoxamine for BPSD showed a more favorable profile in tolerability compared with risperid one, however, ykukansa or fluVoxamine showed a less favorable profile than ris peridone in terms of tolerability.

The response of agitated behavior to pain management in persons with dementia.

Antipsychotic Drug Use and Mortality in Older Adults with Dementia

TLDR
This large, population-based study from Canada assessed the risk for death after dispensation of antipsychotics in older adults with dementia and concluded that improvements in behavioral symptoms with antipsychotic drug treatment do not necessarily lead to improvements in overall quality of life for patients or their caregivers.

Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis

TLDR
Aripiprazole, haloperidol, quetiapine, and risperidone of antipsychotics showed the significant efficacy, while memantine, galantine, and donepezil may provide the modest effectiveness.

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

TLDR
These are the first population-based estimates for neuropsychiatric symptoms in MCI, indicating a high prevalence associated with this condition as well.

The Neuropsychiatric Inventory

TLDR
The NPI is a useful instrument for characterizing the psychopathology of dementia syndromes, investigating the neurobiology of brain disorders with neuropsychiatric manifestations, distinguishing among different dementia syndromees, and assessing the efficacy of treatment.

Comparative safety and efficacy of pharmacological and non-pharmacological interventions for the behavioral and psychological symptoms of dementia: protocol for a systematic review and network meta-analysis

TLDR
The safest and most efficacious treatment strategies for patients with BPSD will be identified from among the authors' most highly ranked treatments from among the published and unpublished literature.

Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial

TLDR
Discontinuation of antidepressant treatment in patients with dementia and neuropsychiatric symptoms leads to an increase in depressive symptoms, compared with those patients who continue with treatment.

Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia

TLDR
It is suggested that a single most effective and safe treatment option for people with dementia may not exist, and insufficient evidence exists on which atypical antipsychotic is both safest and most beneficial across several measures.

Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study

TLDR
Trazodone is not a uniformly safer alternative to atypical antipsychotics, given the similar risk of falls and fractures among older adults with dementia.